Source: http://www.google.com/patents/US7772220?dq=4,923,986
Timestamp: 2015-05-03 14:58:27
Document Index: 660375956

Matched Legal Cases: ['Application No. 200580037307', 'Application No. 200480044467', 'Application No. 200580028815', 'Application No. 200580034884', 'Application No. 05', 'Application No. 04', 'Application No. 05', 'Application No. 05', 'Application No. 05', 'art 2', 'Application No. 181434', 'Application No. 181434', 'Application No. 2000']

Patent US7772220 - Methods and compositions for reducing toxicity of a pharmaceutical compound - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more...http://www.google.com/patents/US7772220?utm_source=gb-gplus-sharePatent US7772220 - Methods and compositions for reducing toxicity of a pharmaceutical compoundAdvanced Patent SearchPublication numberUS7772220 B2Publication typeGrantApplication numberUS 11/251,137Publication dateAug 10, 2010Filing dateOct 14, 2005Priority dateOct 15, 2004Fee statusLapsedAlso published asCN101378769A, EP1940428A1, EP1940428A4, US20060089331, WO2007044062A1, WO2007044062A8Publication number11251137, 251137, US 7772220 B2, US 7772220B2, US-B2-7772220, US7772220 B2, US7772220B2InventorsSeo Hong YooOriginal AssigneeSeo Hong YooExport CitationBiBTeX, EndNote, RefManPatent Citations (85), Non-Patent Citations (266), Referenced by (3), Classifications (21), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetMethods and compositions for reducing toxicity of a pharmaceutical compound
FIG. 4 shows size-fractionated DNA from a commercial DNA ladder (�M�), N18D3 neurons incubated in a control solution (�CTL�), in a solution containing 10 μM cisplatin (�Cis 10 μM�), and in a solution containing 20 μM cisplatin (�Cis 20 μM�);
FIG. 5A shows Western blots of N18D3 neurons incubated for 48 hours in a control solution (�0�), in a solution containing cisplatin at a concentration of 1 μM, 2, μM, 5 μM, 5 μM, 10 μM, or 20 μM using antibodies raised against p53, p21, BCL-2, BCL-XL, BAX, and β-actin;
FIG. 9 shows size-fractionated DNA from a commercial DNA ladder (�M�), N18D3 neurons incubated in a control solution (�CTL�), in a solution containing 20 μM cisplatin (�Cis 20 μM�), and in a solution containing 20 μM cisplatin and 1 mg/mL UDCA (�Cis+UDCA�);
FIG. 10A shows Western blots of N18D3 neurons incubated in a control solution (�Vehicle�), in a solution containing cisplatin (�Cis (μM)�), in a solution containing UDCA (�UDCA (mg/mL)�) using antibodies raised against p53, p21, BCL-2, BCL-XL, BAX, and β-actin;
FIG. 11 shows Western blots of N18D3 neurons incubated in a control solution containing 20 μM cisplatin without pre-treatment (�CTL�), with pre-treatment in a solution lacking UDCA (�Ve�), or with pre-treatment in a solution having the indicated amount of UDCA.
While statins may cause peripheral neuropathy, the incidence may be low. In view of the beneficial effects of statins in terms of cardiovascular protection, this incidence may be regarded as relatively innocuous. The incidence of thalidomide neuropathy may be high (e.g., up to three quarters in some series). Although information on dose dependency is variable, lower cumulative doses may be less toxic. Like thalidomide, bortezomib, a novel proteosome inhibitor, is reportedly effective in the treatment of multiple myeloma and is associated with peripheral neuropathy. Oxaliplatin and epothilone are emerging anticancer drugs with neurotoxic potential. Similarly, leflunomide, a new disease modifying-agent approved for the treatment of rheumatoid arthritis, is reported to cause neuropathy. Antiretroviral agents may be associated with antiretroviral toxic neuropathies (ATN), disorders that may be characterized mostly by sensory symptoms that include �dying back� axonal degeneration of long axons in distal regions, loss of unmyelinated fibers, and variable degree of macrophage infiltration in peripheral nerves and dorsal root ganglia. Some antioxidants may effectively protect neurons from neurotoxicity although the mechanism of this neuroprotection has not been established. Cellular factors that may mediate toxicity and/or antioxidant neuroprotection include p53, Fas, and Fas ligand (Fas-L).
Ursodeoxycholic acid (3α-7β-dihydroxy-5β-cholanic acid) (�UDCA�), which may be a major component of bear bile, may be useful as a pharmaceutical compound for the treatment of and the protection against many types of disease (e.g., liver disease). Its medicinal uses may include the dissolution of radiolucent gall stones and treatment of biliary dyspepsia, primarily biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis and hepatitis C.
Carbohydrates suitable for use in the disclosure include aqueous soluble starch conversion products and aqueous soluble non-starch polysaccharides. According to some embodiments of the present disclosure, aqueous soluble starch conversion products include carbohydrates obtained directly from the partial or incomplete hydrolysis of starch under various pH conditions. Non-limiting examples include maltodextrin, dextrin, liquid glucose, corn syrup solid (dried powder of liquid glucose), and soluble starch, preferably maltodextrin or corn syrup solid, most preferably corn syrup solid. For example, MALTRIN� M200, a corn syrup solid, and MALTRIN� M700 a maltodextrin, both of which are manufactured by GPC�, Grain Processing Corporation of Muscatine, Iowa, may be used. For the purpose of this embodiment, the term �corn syrup� includes both corn syrup and liquid glucose. If a starch conversion product is polymeric, the polymer has at least one reducing end and at least one non-reducing end and may be linear or branched. The molecular weight may be from about 100 mass units to over 106 mass units. High molecular weight aqueous soluble starch conversion products are those having a molecular weight over 105.
In some embodiments of the disclosure, the formulation further comprises emulsifying agents. For the purpose of the disclosure, the term �emulsifying agent� includes emulsifying agents and suspending agents. Non-limiting examples of emulsifying agents include guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.
In some embodiments of the disclosure, the pharmaceutical is cisplatin. Non-limiting examples of other pharmaceutical compounds include hormones, hormone antagonists, analgesic, antipyretics, anti-inflammatory drugs, immunoactive drugs, antineoplastic drugs, antibiotics, anti-inflammatory agents, sympathomimetic drugs, anti-infective drugs, anti-tumor agents, and anesthetics. Further non-limiting examples include drugs that target or effect the gastrointestinal tract, liver, cardiovascular system, and respiratory system. Further non-limiting examples of pharmaceutical compounds include insulin, heparin, calcitonin, ampicillin, octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, apomorphine, yohimbine, trazadone, acyclovir, amantadine �HCl, rimantadine�HCl, cidofovir, delavirdine�mesylate, didanosine, famciclovir, foscarmet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon-α, lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifluridine, valacyclovir�HCl, zalcitabine, zidovudine, indinavir�H2SO4, ritonavir, nelfinavir�CH3SO3H, saquinavir�CH3SO3H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, dacarbazine, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine�HCl, minoxidil, dipyridamole, isoxsuprine�HCl, niacin, nylidrin�HCl, phentolamine, doxazosin�CH3SO3H, prazosin�HCl, terazocin�HCl, clonidine�HCl, nifedipine, molsidomine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide�dinitrate, pentaerythrytol�tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide�HCl, erythromycin, bismuth compound, alprostadil, albuterol, pirbuterol, terbutaline�H2SO4, salmetrol, aminophylline, dyphylline, ephedrine, ethylnorepinephrine, isoetharine, isoproterenol, metaproterenol, nedocromil, oxtriphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone�dipropionate, fluticasone�propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan�HBr, triamcinolone�acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine�HCl, hydrocodone�bitartarate, methadone�HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartarate, glycerin, terpin�hydrate, colfosceril palmitate, atorvastatin�calcium, cervastatin�sodium, fluvastatin�sodium, lovastatin, pravastatin�sodium, simvastatin, picrorrhiza kurroa, andrographis paniculata, moringa oleifera, albizzia lebeck, adhatoda vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin�HCl, econazole�HNO3, miconazole, nystatin, oxiconazole�HNO3, sulconazole�HNO3, cetirizine�2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, fludrocortisone�acetate, flunisolide, fluticasone�propionate, methyl prednisolone, somatostatin, lispro, glucagon, proinsulin, insoluble insulins, acarbose, chlorpropamide, glipizide, glyburide, metformin�HCl, repaglinide, tolbutamide, amino acid, colchicine, sulfinpyrazone, allopurinol, piroxicam, tolmetin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, and trientine.
Clonal N18D3 cells exhibited neuron-like properties not displayed by the parental neuroblastoma. For example, N18D3 hybrid neurons express a specific immunoreactivity to high molecular weight neurofilament protein (NF�H), indicating that they carry neuron-specific phenotypes. N18D3 hybrid neurons also expressed microtubule-associated protein-2 and low and medium molecular weight neurofilaments as shown by immunocytochemistry and sodium channel activity as shown by whole-cell clamp experiments.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3845770Jun 5, 1972Nov 5, 1974Alza CorpOsmatic dispensing device for releasing beneficial agentUS3916899Feb 7, 1974Nov 4, 1975Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passagewayUS4036954Oct 21, 1974Jul 19, 1977Yamanouchi Pharmaceutical Co., Ltd.Stable prostaglandin E group-containing formulationUS4092428Mar 7, 1977May 30, 1978Yamanouchi Pharmaceutical Co., Ltd.Process of preparing stable prostaglandin E group-containing formulationUS4113882May 13, 1976Sep 12, 1978Yamanouchi Pharmaceutical Co., Ltd.Stabilized oral prostaglandin formulation and the process for the preparation thereofUS4320146Oct 2, 1980Mar 16, 1982The Johns Hopkins UniversityTreatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acidsUS4327725Nov 25, 1980May 4, 1982Alza CorporationOsmotic device with hydrogel driving memberUS4585790May 11, 1984Apr 29, 1986Glaxo Group LimitedPharmaceutical compositionsUS4681876Jul 15, 1985Jul 21, 1987National Research Development CorporationAntifungal utility of bile acidsUS4879303Oct 13, 1988Nov 7, 1989Pfizer Inc.Pharmaceutically acceptable saltsUS5057321Jun 13, 1990Oct 15, 1991Alza CorporationDosage form comprising drug and maltodextrinUS5149537Nov 14, 1991Sep 22, 1992Sandoz Ltd.Use of taurocholic acid and its salts as enhancers for calcitonin containing pharmaceutical compositionsUS5157022Nov 22, 1989Oct 20, 1992Adrian BarbulMethod for reducing blood cholesterol using arginineUS5260074Jun 22, 1992Nov 9, 1993Digestive Care Inc.Compositions of digestive enzymes and salts of bile acids and process for preparation thereofUS5292534Mar 25, 1992Mar 8, 1994Valentine Enterprises, Inc.Sustained release composition and method utilizing xanthan gum and an active ingredientUS5300300Apr 1, 1992Apr 5, 1994Alfa Wassermann S.P.A.Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their saltsUS5302398Apr 1, 1992Apr 12, 1994Alfa Wassermann S.P.A.Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acidsUS5302400Jun 22, 1992Apr 12, 1994Digestive Care Inc.Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acidsUS5310560May 5, 1992May 10, 1994Medichemie AgMedicine for the treatment of illnesses of the respiratory organsUS5324514Aug 11, 1993Jun 28, 1994Digestive Care Inc.Compositions of digestive enzymes and salts of bile acids and process for preparation thereofUS5342625Dec 15, 1992Aug 30, 1994Sandoz Ltd.Pharmaceutical compositions comprising cyclosporinsUS5380533Apr 1, 1992Jan 10, 1995Alfa Wassermann S.P.A.Gastroresistant pharmaceutical formulations for oral administration containing bile acidsUS5446026Feb 19, 1993Aug 29, 1995Advanced Peptides & Biotechnology SciencesPotent non-opiate analgesicUS5470581Dec 15, 1992Nov 28, 1995Berwind Pharmaceutical Services, Inc.Aqueous maltodextrin and cellulosic polymer film coatingsUS5484776Oct 14, 1993Jan 16, 1996Synepos AktiengesellschaftProcess for the production of stable liquid form of beta-blocker-containing medicaments with controlled release of the active constituent for oral administrationUS5516523May 16, 1994May 14, 1996Theratech, Inc.Transmucosal delivery of macromolecular drugsUS5534505Aug 25, 1994Jul 9, 1996Medichemie AgUrsodeoxycholic acid-containing medicament in a liquid adminstration formUS5578304May 4, 1995Nov 26, 1996Digestive Care Inc.Compositions of digestive enzymes and salts of bile acids and process for preparation thereofUS5599926Jan 27, 1994Feb 4, 1997The Trustees Of Columbia University In The City Of New YorkA4 B6 macrotricyclic enantioselective receptors for amino acid derivatives, and other compoundsUS5641767Sep 12, 1995Jun 24, 1997Hoechst AktiengesellschaftModified bile acids process for their preparation and their useUS5653987May 16, 1995Aug 5, 1997Modi; PankajLiquid formulations for proteinic pharmaceuticalsUS5686588Aug 16, 1995Nov 11, 1997Yoo; Seo HongAmine acid salt compounds and process for the production thereofUS5750104May 29, 1996May 12, 1998Digestive Care Inc.High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewithUS5750707Mar 6, 1995May 12, 1998Pfizer Inc.Separation of the enantiomers of amlodipine via their diastereomeric tartratesUS5843929Mar 22, 1996Dec 1, 1998Mayo Foundation For Medical Education And ResearchChemoprevention of metachronous adenomatous colorectal polypsUS5846964Jul 19, 1994Dec 8, 1998Tokyo Tanabe Company LimitedHepatitis C virus proliferation inhibitorUS5858998Sep 30, 1997Jan 12, 1999Dr. Falk Pharma GmbhBudesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseasesUS5863550Feb 23, 1994Jan 26, 1999Tokyo Tanabe Company LimitedCholestasis ameliorantUS5898028Mar 20, 1998Apr 27, 1999Novo Nordisk A/SMethod for producing powder formulation comprising an insulinUS5945411Sep 23, 1998Aug 31, 1999Mayo Foundation For Medical Education And ResearchChemoprevention of metachronous adenomatous colorectal polypsUS5965164Apr 29, 1996Oct 12, 1999Fuisz Technologies Ltd.Recipient-dosage delivery systemUS5977070Aug 29, 1995Nov 2, 1999Piazza; Christin TeresaPharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosisUS6099859Mar 20, 1998Aug 8, 2000Andrx Pharmaceuticals, Inc.Controlled release oral tablet having a unitary coreUS6210699Apr 1, 1999Apr 3, 2001Watson Pharmaceuticals, Inc.Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavityUS6245753Apr 27, 1999Jun 12, 2001Mediplex Corporation, KoreaAmphiphilic polysaccharide derivativesUS6251428 *Jul 20, 1999Jun 26, 2001Seo Hong YooPreparation of aqueous clear solution dosage forms with bile acidsUS6309663 *Aug 17, 1999Oct 30, 2001Lipocine Inc.Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agentsUS6635628 *Jun 17, 2002Oct 21, 2003The George Washington UniversityMethods of administering camptothecin compounds for the treatment of cancer with reduced side effectsUS7034006Jan 10, 2001Apr 25, 2006Yissum Research Development Company Of The Hebrew University Of JerusalemUse of lipid conjugates in the treatment of diseaseUS7166299 *Dec 4, 2002Jan 23, 2007Seo Hong YooPreparation of aqueous clear solution dosage forms with bile acidsUS7303768Feb 5, 2001Dec 4, 2007Seo Hong YooPreparation of aqueous clear solution dosage forms with bile acidsUS20010046521Mar 12, 2001Nov 29, 2001Michael ZasloffTreatment of carcinomas using squalamine in combination with other anti-cancer agents or modalitiesUS20020031558 *Feb 5, 2001Mar 14, 2002Yoo Seo HongPreparation of aqueous clear solution dosage forms with bile acidsUS20020081361Jul 16, 2001Jun 27, 2002Allan TowbDrying of neotame with co-agentsUS20030044413Sep 18, 2002Mar 6, 2003Regents Of The University Of MinnesotaMethods of limiting apoptosis of cellsUS20050158408Nov 24, 2004Jul 21, 2005Yoo Seo H.Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereofUS20060051319 *Aug 30, 2005Mar 9, 2006Yoo Seo HNeuroprotective effect of solubilized UDCA in focal ischemic modelUS20060089331Oct 14, 2005Apr 27, 2006Yoo Seo HMethods and compositions for reducing toxicity of a pharmaceutical compoundUS20060142241 *Oct 31, 2005Jun 29, 2006Yoo Seo HMethods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosisUS20060188530 *Mar 10, 2006Aug 24, 2006Yoo Seo HBile preparations for gastrointestinal disordersUS20070072828 *Sep 15, 2006Mar 29, 2007Yoo Seo HBile preparations for colorectal disordersUS20080057133 *Nov 2, 2007Mar 6, 2008Yoo Seo HPreparation of Aqueous Clear Solution Dosage Forms with Bile AcidsAU3735899A Title not availableCN1450914AFeb 5, 2001Oct 22, 2003柳署弘Preparation of aqueous clear solution dosage forms with bile acidsEP0086705A1Feb 8, 1983Aug 24, 1983S.A. PANMEDICA Soci�t� dite:Aqueous solution of ursodeoxycholic acid for therapeutic uses, process for its preparation and its utilization for the treatment of cholelithiasisEP0312052A1Oct 13, 1988Apr 19, 1989Syntex (U.S.A.) Inc.Intranasal administration of polypeptides in powdered formEP0599282A1Nov 24, 1993Jun 1, 1994BIOPROGRESS S.p.A.Pharmaceutical compositions containing ursodeoxycholic acidEP1255566A2Feb 5, 2001Nov 13, 2002Seo Hong YooPreparation of aqueous clear solution dosage forms with bile acidsFR2710267A1 Title not availableJPH0624991A Title not availableJPS5522616A Title not availableJPS61171421A Title not availableJPS62153220A Title not availableJPS63104925A Title not availableJPS63243031A Title not availableWO1999061481A1May 14, 1999Dec 2, 1999Mediplex Corp KoreaAmphiphilic polysaccharide derivativesWO2000004875A2Jul 20, 1999Feb 3, 2000Seo Hong YooPreparation of aqueous clear solution dosage forms with bile acidsWO2000010552A2 *Aug 24, 1999Mar 2, 2000Global Vascular Concepts IncUse of anti-angiogenic agents for inhibiting vessel wall injuryWO2001056547A2Feb 5, 2001Aug 9, 2001Seo Hong YooPreparation of aqueous clear solution dosage forms with bile acidsWO2004012686A2Aug 6, 2003Feb 12, 2004Garvey David SNitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of useWO2004043342A2Oct 8, 2003May 27, 2004Walter C LowMethods of treating injuries of the nervous system associated with hemorrhageWO2004096123A2Apr 2, 2003Nov 11, 2004Walter C LowMethods of promoting cell viabilityWO2006026555A2Aug 30, 2005Mar 9, 2006Seo Hong YooNeuroprotective effect of solubilized udca in focal ischemic modelWO2006050165A2Oct 31, 2005May 11, 2006Seo Hong YooMethods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosisWO2006057637A1Nov 24, 2004Jun 1, 2006Seo Hong YooDried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof* Cited by examinerNon-Patent CitationsReference1"An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients", ClinicalTrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00000650;jsessionid=AF8903A542A345FA86641E2A559AC8C9?order=1, pp. 6, Feb. 27, 2006.2"Clean, Beautiful, Healthy Life ", LG Household & Health Care, http://www.lgcare.com/english/aboutus/06.html, pp. 3, Feb. 27, 2006.3"Colfosceril Palmitate", Tiscali, http://www.tiscali.co.uk/lifestyle/healthfitness/health-advice/netdoctor/archive/100003422.html , pp. 2, 1998-2004.4"Dacarbazine", Aidsmap Treatment and Care, http://www.aidsmap.com/en/docs/9685F4D7-D57C-4F10-A41F-D5EDF7811B3A.asp , pp. 1, Feb. 6, 2006.5"Dacarbazine", NCI Terminology Browser, http://nciterms.nci.nih.gov/NCIBrowser/PrintableReport.jsp?dictionary=NCI-Thesaurus&code=C411 , pp .3, Nov. 2005.6"Denavir", PDRhealth, http://www.pdrhealth.com/drug info/rxdrugprofiles/drugs/den1123.shtml , pp. 2, Feb. 8, 2006.7"Diethyldithiocarbamate", http://nciterms.nci.nih.gov/NCIBrowser/ConceptRecords.jsp?, pp. 2, Feb. 6, 2006.8"Drug Information: Bronchodilators, Andrenergic (Inhalation)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202095.html , pp. 12, Jun. 25, 2003.9"Drug Information: Celecoxib", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a699022.html , pp. 4, Jan. 1, 2006.10"Drug Information: Dacarbazine", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682750.html , pp. 2, Apr. 1, 2003.11"Drug Information: Dyphylline (Systemic)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202752.html , pp. 4, Jun. 14, 1999.12"Drug Information: Hydralazine", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682246.html , pp. 3, Apr. 1, 2003.13"Drug Information: Isoxsuprine (Systemic)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202310.html , pp. 4, Jul. 15, 1994.14"Drug Information: Nylidrin (Systemic)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202416.html , pp. 3, May 14, 1993.15"Maltrin Maltodextrins & Corn Syrup Solids Chemical and Physical Properties" GPC Technical Bulletin, TB31-021296, Grain Processing Corp. (Brochure + 4 pages), 1999.16"Powered by Dorland's Illustrated Medical Dictionary: E", MerckSource, http://www.mercksource.com/pp/us/cns/cns-hl-dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandszSzdorlandzSzdmd-e-17zPzhtm, pp. 3, Feb. 27, 2006.17"Proventil", PDR Health, http://www.pdrhealth.com/drug-info/rxdrugprofiles/drugs/pro1360.shtml, pp. 5, Feb. 8, 2006.18"Saccharide Composition Typical Carbohydrate Profiles" GPC Technical Bulletin TB30-021296, Grain Processing Corp. (1 page), 1999.19"Selenium", PDR Health, http://www.pdrhealth.com/drug-info/nmdrugprofiles/nutsupdrugs/sel-0232.shtml, pp. 8, Feb. 27, 2006.20"Zovirax", PDRhealth, http://www.pdrhealth.com/drug info/rxdrupprofiles/drugs/zov1505.shtml , pp. 4, Feb. 8, 2006.21"Colfosceril Palmitate", Tiscali, http://www.tiscali.co.uk/lifestyle/healthfitness/health�advice/netdoctor/archive/100003422.html , pp. 2, 1998-2004.22"Dacarbazine", NCI Terminology Browser, http://nciterms.nci.nih.gov/NCIBrowser/PrintableReport.jsp?dictionary=NCI�Thesaurus&code=C411 , pp .3, Nov. 2005.23"Pharmaceutical Necessities", Remington: The Science and Practice of Pharmacy, Mack Printing Co., Easton, Pennsylvania (1995) pp. 1409-1410.24"Powered by Dorland's Illustrated Medical Dictionary: E", MerckSource, http://www.mercksource.com/pp/us/cns/cns�hl�dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandszSzdorlandzSzdmd�e�17zPzhtm, pp. 3, Feb. 27, 2006.25"Proventil", PDR Health, http://www.pdrhealth.com/drug�info/rxdrugprofiles/drugs/pro1360.shtml, pp. 5, Feb. 8, 2006.26"Selenium", PDR Health, http://www.pdrhealth.com/drug�info/nmdrugprofiles/nutsupdrugs/sel�0232.shtml, pp. 8, Feb. 27, 2006.27 *2006 Chemical Abstracts catalog, published 2006 by Chemical Abstracts Service, p. 52.2827th Annual Meeting of the Korean Neurological Association; "Oral Presentation"; Journal of the Korean Neurological Association; vol. 26, Suppl. 2; pp. 3, 2008.29A. Benjamin Suttle and Kim L. R. Brouwer, "Regional Gastronintestinal Absorption of Ranitidine in the Rat", Pharmaceutical Research, (1995) Vol. 12, No. 9 pp. 1311-1315. 1995.30A. Bj�rkland and T.H. Totterman, "Is Primary Biliary Cirrhosis an Autoimmune Disease?", Scand J. Gastroenteral (1994) 29 Suppl. 204:32-9.31A. Stiehl, "Ursodeoxycholic Acid Therapy in Treatment of Primary Sclerosing Cholangitis", Scand J Gastroenterol (1994) 29 Suppl. 204:59-61.32A.C. Peltier et al.; "Recent Advances in Drug-Induced Neuropathies"; Current Opinion in Neurology, vol. 15; pp. 633-638, 2002.33A.D. McNaught, "Nomenclature of Carbohydrates", Pure and Applied Chemistry, vol. 68, pp. 1919-2008, 1996.34A.F. Hofmann, "Pharmacology of Ursodeoxycholic Acid, an Enterohepatic Drug", Scand J. Gastroenteral (1994) 29 Suppl. 204:1-15.35Aigner A and Bauer A, "Bile acids, Long known active substances with a future", Med Monatsschr Pharm (1988) (11): 369-75.36Angelin et al., "Effects of Ursodeoxycholic Acid on Plasma Lipids", Scand J. Gastroenterol. (1994) 29 Suppl 204:24-26.37Armstrong et al., "The Hydrophobic-Hydrophilic Balance of Bile Salts. Inverse Correlation between Reverse-Phase High Performance Liquid Chromatographic Mobilities and Micellar Cholesterol-Solubilizing Capacities", J. Lipid Research, (1982) vol. 23 pp. 70-80.38 *Barbarotto et al., "Differential Effects of Chemotherapeutic Drugs Versus the MDM-2 Antagonist Nutlin-3 on Cell Cycle Progression and Induction of Apoptosis in SKW6.4 Lymphoblastoid B-Cells" Journal of Cellular Biochemistry (2008) vol. 140, pp. 595-605.39Beuers et al., "Ursodeoxycholic Acid for Treatment of Primary Sclerosing Cholangitis: A Placebo-controlled Trial", Hepatology. (1992) vol. 16, No. 3, pp. 707-714.40Binek et al., "Bedeutung von Ursodeoxychols�ure bei der Eradikation von Helicobacter pyloni", Schweitz Med Wochenschr (1996) 126 (Suppl. 79): 44S-46S.41Boberg et al., "Etiology and Pathogenesis in Primary Sclerosing Cholangitis", Scand J. Gastroenterol (1994) 29 Suppl. 204:47-58.42Bode et al., "Polymorphism in Helicobacter pylori�a key function in recurrence of infection", Medizinische Klinik, (1992) 87(4):179-84.43Brazilian Office Action for Patent Application PI 9912395-9, 6 pages, Dec. 5, 200844Buckley et al., "Controlled Release Drugs in Overdose Clinical Consideration", Drug Safety (1996) vol. 12, No. 1 pp. 73-84.45C.A. Ventura et al.; "Improvement of Water Solubility and Dissolution Rate of Ursodeoxycholic Acid and Chenodeoxycholic Acid by Complexation With Natural and Modified beta-Cyclodextrins"; International Journal of Pharmaceutics; vol. 149; pp. 1-13, 1997.46C.A. Ventura et al.; "Improvement of Water Solubility and Dissolution Rate of Ursodeoxycholic Acid and Chenodeoxycholic Acid by Complexation With Natural and Modified β-Cyclodextrins"; International Journal of Pharmaceutics; vol. 149; pp. 1-13, 1997.47C.D. Keene et al.; "A Bile Acid Protects Against Motor and Cognitive Deficits and Reduces Striatal Degeneration in the 3-Nitropropionic Acid Model of Huntington's Disease"; Experimental Neurology, vol. 171; pp. 351-360, 2001.48C.J. Newton et al.; "Fluvastin Induces Apoptosis of Vascular Endothelial Cells: Blockade by Glucocorticoids"; Cardiovascular Surgery, vol. 11, No. 1; pp. 52-60, 2003.49C.M.P. Rodrigues et al.; "Bilirubin and Amyloid-β Peptide Induce Cytochrome c Release Through Mitochondrial Membrane Permeabilization"; Molecular Medicine, vol. 6, No. 11; pp. 936-946, 2000.50C.M.P. Rodrigues et al.; "Neuroprotection by a Bile Acid in an Acute Stroke Model in the Rat"; Journal of Cerebral Blood Flow & Metabolism, vol. 22; pp. 463-471, 2002.51C.M.P. Rodrigues et al.; "The Therapeutic Effects of Ursodeoxycholic Acid as an Anti-Apoptotic Agent"; Expert Opin. Investig. Drugs, vol. 10, No. 7; pp. 1243-1253, 2001.52Cannon et al. "Reduction of pain on intravenous infusion with bile salt formulations for a macrolide antibiotic" International Journal of Pharmaceutics, vol. 114, No. 1 (pp. 65-74), Jul. 13, 1994.53Carey et al., "Micelle Formation by Bile Salts", Arch Intern Med, (1972) vol. 130, pp. 506-527.54Carey, MD et al. "Micelle Formation by Bile Salts Physical-Chemical and Thermodynamic Considerations" Arch. Intern. Med., vol. 130 (pp. 506-527), Oct. 1972.55Cecilia M.P. Rodrigues et al., "Ursodeoxycholic Acid May Inhibit Deoxycholic Acid-Induced Apoptosis by Modulating Mitochondrial Transmembrane Potential and Reactive Oxygen Species Production", Molecular Medicine, vol. 4, pp. 165-178, 1998.56Chad Silverberg; "Atorvastatin-Induced Polyneuropathy"; www.PubMed.com ; pp. 5, Nov. 4, 2003.57Chazouilleres et al., "Ursodeoycholic Acid for Primary Sclerosing Cholangitis", J. Hepatology, (1990) vol. 11 pp. 120-123.58 *Chemical Abstracts Registry entry 191595-91-2, "Bamet R2" copyright 2007 American Chemical Society.59 *Chemical Abstracts Registry entry 265093-50-3, "Bamet UD2" copyright 2007 American Chemical Society.60 *Chemical Abstracts Registry entry 64480-66-6 "Glycoursodeoxycholic acid" copyright 2007 American Chemical Societ.61Chinese Office Action for Patent Application 01804549.9, 6 pages, Oct. 30, 2008.62Chinese Office Action; Application No. 200580037307.8; pp. 6, May 15, 2009.63Chu et al. "Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia" Brain Research 1016 (pp. 145-153), 2004.64Cirillo N.W. and F.R. Zwas., "Ursodeoxycholic Acid in the Treatment of Chronic Liver Disease", Am J Gastroenterol (1994) vol. 89, No. 9 pp. 1447-1452.65CN Office Action; Application No. 200480044467.0; pp. 7, Mar. 27, 2009.66CN Office Action; Application No. 200580028815.X; pp. 10, Mar. 13, 2009.67CN Office Action; Application No. 200580034884.1; pp. 6, Mar. 27, 2009.68 *Cole et al., "Efficacy and Safet of Perhexiline Maleate in Refractory Angina" Circulation (1990) vol. 81 pp. 1260-1270.69Colombo et al., "Effects of Ursodeoxycholic Acid Therapy for Liver Disease Associated with Cystic Fibrosis", J. of Pediatrics, (1990) vol. 117, No. 3 pp. 482-489.70Colombo et al., "Ursodeoxycholic Acid Therapy in Cystic Fibrosis-associated Liver Disease: A Dose-response Study", Hepatology, (1992) vol. 16, No. 4 pp. 924-930.71Communication pursuant to Article 94(3) EPC; Application No. 05 813 305.9-1216; pp. 7, Mar. 7, 2008.72 *Coudron et al., "In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori" Journal fo Antimicrobial Chemotherapy (1998) vol. 42 pp. 657-660.73Crosignani, et al., "Clinical Pharamcokinetics of Therapeutic Bile Acids", Clin. Pharmacokinet, (1996) vol. 30, No. 5 pp. 333-358.74D. Chapman-Shimshoni et al.; "Simvastatin Induces Apoptosis of B-CLL cells by Activation of Mitochondrial Caspase 9"; Experimental Hematology, vol. 31; pp. 779-783, 2003.75D. Gaist et al.; "Statins and Risk of Polyneuropathy"; Neurology, vol. 58; pp. 1333-1337, May 2002.76D. Lapenna et al.; "Antioxidant Properties of Ursodeoxycholic Acid"; Biochemical Pharmacology, vol. 64; pp. 1661-1667, 2002.77D.L. Nelson, "Carbohydrates and Glycobiology", Lehninger Principles of Biochemistry,Fourth Edition, pp. 238-271, 2005.78D.S. Alberts et al., "Phase III Trial of Ursodeoxycholic Acid to Prevent Colorectal Adenoma Recurrence", Journal of National Cancer Institute, vol. 97, No. 11, pp. 846-853, Jun. 1, 2005.79Database WPI Section Ch, Week 198824 Derwent Publications Ltd., London, GB, AN-1988-165730 XP002337363 & JP 63104925 A, 1988.80Database WPI Section Ch, Week 198846 Derwent Publications Ltd., London, GB, AN-1988-327783 XP002337364 & JP 63243031 A, 1988.81De Caprio et al., "Bile Acid and sterol solubilization in 2-hydroxypropyl-β-cyclodextrin", Journal of Lipid Research, (1992) vol. 33, pp. 441-443.82Deborah F. Gelinas; "Riluzole"; ALS and Other Motor Neuron Disorders,(Suppl 4); pp. 3-4, 2000.83Dioguardi et al., "The role of oral branched-chain amino acids (BCAAs) in the elevation of plasma ammonia (pNH3)", Chapter 68, in Advances in Ammonia Metabolism and Hepatic Encephalopathy, Soeters et al., eds., (1988) Elsevier Science Publishers B.V., pp. 527-533. 1988.84Dominguez et al. "Low in Vivo Toxicity of a Novel Cisplatin-Ursodeoxycholic Derivative (Barnet-UD2) with Enhanced Cytostatic Activity versus Liver Tumors" Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 3 (pp. 1106-1112), Jan. 16, 2001.85Dressman et al., "Gastrointestinal Parameters that Influence Oral Medications", J. of Pharmaceutical Sciences, (1993) vol. 82, No. 9 pp. 857-872.86Drug Name: Tauroursodeoxycholic Acid (TUDCA), TUDCA-Various/UDCA (Ursodiol-Actigall, Watson Pharmacceuticals, Novartis, Generics), 7 pages, 2004.87 *Dudley et al., "Attenuated p53 activation in tumor-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine" British Journal of Cancer (2008) vol. 99, pp. 118-125.88E. Diguet et al.; "Effects of Riluzole on Combined MPTP + 3-Nitropropionic Acid-Induced Mild to Moderate Striatonigral Degeneration in Mice"; Journal of Neural Transmission; pp. 19, 2004.89E. Nagy et al., "Imuthiol Inhibits the Etoposide-Induced Apoptosis in HL-60 Cells" Immunology Letters vol. 64, pp. 1-4, 1998.90EMEA/CHMP/EWP Workshop; "Slowing the Progression of Neurodegenerative Diseases: Medicinal Productions (MP) Clinical Development"; European Medicines Agency, Pre-authorisation Evaluation of Medicines for Human Use; http://www.emea.europa.eu; pp. 15, Oct. 2, 2006.91European Office Action for Application No. 04 812 094.3, 8, Applicant: Seo Hong Yoo, 8 pages, Dec. 17, 2007.92European Office Action for Application No. 05 820 886.9, 3 pages, Nov. 14, 2008.93European Office Action; Application No. 05 792 858.2-2123; pp. 4, May 20, 2009.94European Office Action; Application No. 05 813 305.9-1216; pp. 16, Jan. 19, 2010.95F. Lanzarotto et al., "Effect of Long-Term Simvastatin Administration as an Adjunct to Ursodeoxycholic Acid: Evidence for a Synergistic Effect on Biliary Bile Acid Composition but Not on Serum Lipids in Humans", GUT, (1999) vol. 4 pp. 552-556.96F. S. Giorgi et al., "The role of norepinephrine in epilepsy: from the bench to the bedside" Neurosci. Behavioral. Rev.. vol. 28, pp. 507-524, 2004.97Fiaccadori et al., "The effect of dietary supplementation with branch-chain amino acids (BCAAs) vs. casein in patients with chronic recurrent portal systemic encephalopathy: a controlled trial", pp. 489-497. (1988) Elsevier Science Publishers B.V. Advances in ammonia metabolism and hepatic encephalopathy.98 *Fox et al., "Short Analytical Review: Mechanism of Action for Leflunomide in Rheumatoid Arthritis" Clinical Immunology (1999) vol. 93 No. 3, pp. 198-208.99Fried et al., "Ursodeoxycholic Acid Treatment of Refractory Chronic Graft-versus-Host Disease of the Liver", Annals of Internal Medicine, (1992) 116:624-629.100Fr�mming, "Cyclodextrin Derivatives", Cyclodextrins in Pharmacy, Chapter 2, pp. 19-32, 1994.101Fr�mming, "Cyclodextrins", Cyclodextrins in Pharmacy, Chapter 1, pp. 1-18, 1994.102G. Buck, "Campylobacter pylori and Gastrroduodenal Disease". Clinical Microbiology Reviews, (1990) vol. 3, No. 1 pp. 1-12.103G. H. P. Te Wierik et al., "Preparation, Characterization and Pharmaceutical Application of Linear Dextrins: IV. Drug Release from Capsules and Tablets Containing Amylodextrin", International J. of Pharmaceutics, (1993) vol. 98 pp. 219-224.104G.D. Ghadge et al.; "Mutant Superoxide Dismutase-1-Linked Familial Amyotrophic Lateral Sclerosis: Molecular Mechanisms of Neuronal Death and Protection"; The Journal of Neuroscience, vol. 17, No. 22; pp. 8756-8766, Nov. 15, 1997.105Gerhard Schmid, "Preperation and Industrial Production of Cyclodextrins", Comprehensive Supramolecular Chemistry, vol. 3, pp. 41-56, 1996.106Gerrit H. P. Te Wierik et al., "Preparation, Characterization, and Pharmaceutical Application of Linear Dextrins, I. Preparation and Characterization of Amylodextrin, Metastable Amylodextrins, and Metastable Amylose", Pharmaceutical Research, (1993) vol. 10, No. 9 pp. 1274-1279.107Gerritt H. P. Te Wierik et al., "Preparation, Characterization, and Pharmaceutical Application of Linear Dextrins. II. Complexation and Dispersion of Drugs with Amylodextrin by Freeze-Drying and Kneading", Pharmaceutical Research, vol. 10, No. 9 pp. 1280-1284.108Golub et al., "Physiologic Considerations in Drug Absorption from the Gastrointestinal Tract", J. Allergy Clin. Immunol., (1986) vol. 78, No. 4, Part 2 pp. 689-694.109Gordon et al., "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts", Proc. Natl. Acad. Sci., (1985) vol. 82 pp. 7419-7423.110 *Govindarajan et al., "Irinotecan and thalidomide in metastatic colorectal cancer" Oncology (2000) vol. 14 No. 12 suppl 13, abstract.111 *Graham et al., "Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance" Alimentary Pharmacology and Therapeutics (2001) vol. 15 pp. 513-518.112H.P.R. Bootsma et al.; "beta-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: in Vitro and in Vivo Evaluation of Spray-Dried Diazepam-beta-Cyclodextrin Products"; Inernation Journal of Pharmaceutics, vol. 51; pp. 213-223, 1989.113H.P.R. Bootsma et al.; "β-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: in Vitro and in Vivo Evaluation of Spray-Dried Diazepam-β-Cyclodextrin Products"; Inernation Journal of Pharmaceutics, vol. 51; pp. 213-223, 1989.114H.R. Horton, "Carbohydrates", Principles of Biochemistry, Second edition, pp. 228-234, 1996.115Hammad et al. "Increasing Drug Solubility by Means of Bile Salt-Phosphatidylcholine-Based Mixed Micelles" European J. of Pharmaceutics and Biopharmaceutics, vol. 46 (pp. 361-367), 1998.116Hammad et al. "Solubility and Stability of Tetrazepam in Mixed Micelles" European J. of Pharmaceutical Sciences, vol. 7, (pp. 49-55) 1998.117Han et al., "The Interaction of pH, Bile and Helicobacter pylori May Explain Duofenial Ulcer", American Journal of Gastroenterology (1996) vol. 91, No. 6, pp. 1135-1137.118 *Hempfling et al., "Systematic review: ursodeoxycholic acid-adverse effects and drug interactions" Alimentary Pharmacology and Therapeutics (2003) vol. 18 pp. 963-972.119 *Hempfling et al., "Systematic review: ursodeoxycholic acid�adverse effects and drug interactions" Alimentary Pharmacology and Therapeutics (2003) vol. 18 pp. 963-972.120Higginbottom et al., International Journal of Pharmaceutics, vol. 109, pp. 173-180, 1994.121Hirai et al. "Mechanisms for the Enhancement of the Nasal Absorption of Insulin by Surfactants" International J. of Pharmaceutics, vol. 9 (pp. 173-184), 1981.122Hirai et al., "Effect of Surfactants on the Nasal Absorption of Insulin in Rats", International J. of Pharmaceutics, (1981) vol. 9 pp. 165-172. 1981.123Hirai et al., "Mechanisms for the Enhancement of the Nasal Absorption of Insulin by Surfactants", International J. Phamaceutics, (1981) vol. 9 pp. 173-184.124Hofmann et al.; "Bile Acid Solubility and Preperation in Vitro and in Vivo: The Role of Conjugation, pH, and Ca2+ Ions"; Journal of Lipid Research, vol. 33; pp. 617-626, 1992.125Hollander et al. "Intestinal Absorption of Aspirin Influence of pH, Taurocholate, Ascorbate and Ethanol" J. of Lab. Clin. Med., vol. 98, No. 4 (pp. 591-595), Oct. 1980.126Hollander et al., "Intestinal Absorption of Aspirin, Influence of pH, Taurocholate, Ascorbate and Ethanol", J. Lab. Clin. Med., (1981) vol. 98, No. 4 pp. 591-595.127 *Howard et al., Suramin Increases p53 Protein Levels but Does Not Activate the p53-dependent G1 Checkpoint Clinical Cancer Research (1996) vol. 2 pp. 269-276.128Hubner et al., "Enhancement of Monocyte Antimycobacterial Activity by Diethyldithiocarbamate (DTC)" Int. J. Immunopharmac, vol. 13, pp. 1067-1072, 1991.129I. Bj�rkhem, "Inborn Errors of Metabolism with Consequences for Bile Acid Biosynthesis: A Minireview", Scand J. Gastroenteral (1994) 29 Suppl. 204:68-72.130Igimi et al. "ph-Solubility Relations of Chenodeoxycholic and Ursodeoxycholic Acids: Physical-Chemical Basis for Dissimilar Solution and Membrane Phenomena" J. of Lipid Research, vol. 21 (pp. 72-90), 1980.131Igimi et al., "pH-Solubility Relations of Chenodeoxycholic and Ursodeoxycholic Acids: Physical-Chemical Basis for Dissimilar Solution and Membrane Phenomena", J. Lipid Research, (1980) vol. 21 pp. 72-90.132Ikeda et al., "Antioxidant Nutrients and Hypoxia/Ischemia Brain Injury in Rodents", Toxicology vol. 189, pp. 55-61, 2003.133International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2004/039507 (21 pages), Jun. 7, 2007.134International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2005/030679 (9 pages), Mar. 6, 2007.135International Preliminary Report on Patentability for International Application No. PCT/US2005/037211 (10 pages), Apr. 26, 2007.136International Preliminary Report on Patentability for International Application No. PCT/US2005/039089 (9 pages), May 10, 2007.137International Preliminary Report on Patentability; PCT/US2006/036325; pp. 8, Mar. 26, 2009.138International Search Report and Written Opinion for International Application No. PCT/US2005/037211 (16 pages), Feb. 13, 2007.139International Search Report and Written Opinion for International Application No. PCT/US2006/036325 (13 pages), Jun. 4, 2007.140International Search Report and Written Opinion; PCT/US2005/039089; pp. 15, Mailed: May 24, 2006.141Invernizzi et al. "Differences in the Metabolism and Disposition of Ursodeoxycholic Acid and of its Taurine-Conjugated Species in Patients with Primary Biliary Cirrhosis" Hepatology, vol. 29, No. 2 (pp. 320-327), Feb. 1999.142Isreal Office Action; Application No. 181434; pp. 1, Sep. 7, 2009.143Isreali Office Action; Application No. 181434; pp. 12, Mar. 22, 2009.144 *Itoh et al., "Antibacterial action of bile acids against Helicobacter pylori and changes in its ultrastructural morphology: effect of unconjugated dihydroxy bile acid" Journal of Gastroenterology (1999) vol. 34 pp. 571-576.145Itoh et al.; "Antibacterial action of bile acids against Helicobacteria pylori and changes inits ultrastructural morphology: effect of unconjugated dihydroxy bile acid"; J. Gastroenterol, vol. 34, pp. 571-576, 1999.146J.F. Dasta et al.; "Comparison of Visual and Turbidimetric Methods for Determining ShortTerm Compatibility of Intravenous Critical-Care Drugs"; American Journal of Hospital Pharmacy; vol. 45; pp. 2361-2366, Nov. 1988.147Japanese Office Action (w/translation); Application No. 2000-560868; pp. 10, Oct. 9, 2009.148 *Jones et al., "The role of dexamethasone in the modification of misonidazole pharmacokinetics" British Journal of Cancer (1983) vol. 48 No. 4, pp. 553-557.149Jorgensen et al., "Characterisation of patients with a complete biochemical response to ursodeoxycholic acid", GUT (1995) 36:935-938, .150K. Bodin et al., "Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4" J. Biol. Chem. vol. 276, pp. 38685-38689, Oct. 19, 2001.151K. Einarsson, "Effect of Urodeoxycholic Acid on Hepatic Cholesterol Metabolism", Scand J. Gastroenteral (1994) 29 Suppl. 204:19-23.152K. M�ller, "Structural Aspects of Bile Salt-Lecithin Mixed Micelles", Hepatology, (1984) vol. 4, No. 5 pp. 134S-137S.153K.G. Rajesh et al., "Hydrophilic Bile Salt Ursodeoxycholic Acid Protects Myocardium Against Reperfusion Injury in a P13K/Akt Dependent Pathway", Journal of Molecular and Cellular Cardiology, vol. 39, pp. 766-776, 2005.154Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 513-515 (Cisplatin), Jan. 1, 1999.155Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 556-558 (Paclitaxel), Jan. 1, 1999.156Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 593 (Sumarin), Jan. 1, 1999.157Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 607-609 (Didanosine), Jan. 1, 1999.158Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 629-630 (Zalcitabine), Jan. 1, 1999.159Keith D. Lindor, M.D., "Ursodiol for Primary Sclerosing Cholangitis", The New England Journal of Medicine, (1997) vol. 336, No. 10., pp. 691-695.160Kimura et al., "A 1-h Topical Therapy for the Treatment of Helicobacter pylori Infection", Am. J. Gastercenterol. (1995) vol. 90, No. 1, pp. 60-63.161Kimura et al.; "A Case of Cerebrotendinous Xanthomatosis: Effects of Ursodeoxycholic Acid Administration on Serum Bile Acids and Cholestanol"; Jap J Med, vol. 21, No. 3; pp. 210-215, Jul. 1982.162Kirk et al.; "Inclusion Compounds"; Encyclopedia of Chemical Technology, Fourth Edition; vol. 14; pp. 125-135, 1995.163Knopp et al., "Long-Term Blood Cholesterol-Lowering Effects of a Dietary Fiber Supplement", Am J Pre. Med (1999) 17(1):18-23.164L. Dupuis et al.; "Evidence for Defective Energy Homeostasis in Amyotrophic Lateral Sclerosis: Benefit of a High-Energy Diet in a Transgenic Mouse Model"; www.pnas.org/cgi/doi/10.1073/pnas.0402026101 ; PNAS, Jul. 27, 2004, vol. 101, No. 30, pp. 11159-11164.165 *Lee et al., "Regulation of Cyclin-Dependent Kinase 5 and p53 py ERK1/2 Pathway in the DNA Damage-Induced Neuronal Death" Journal of Cellular Physiology (2007) vol. 210 pp. 784-797.166Lehninger et al., "Carbohydrates and Glycobiology", Principles of Biochemistry, pp. 301-307, 2000.167Leuschner et al., "Oral Budesonide and Ursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: Results of a Prospective Double-Blind Trial", Gastroenterology, (1999) vol. 117 pp. 918-925.168Lindor et al., "The Combination of Ursodeoxycholic Acid and Methotrexate for Patients with Primary Biliary Cirrhosis: The Results of a Pilot Study", Hepatology (1995) vol. 22, No. 4 pp. 1158-1162.169Lindor et al., "Ursodeoxycholic Acid in the Treatment of Primary Biliary Cirrhosis", Gastroenteral (1994) 106:1284-1290.170M. F�ocking et al; "Statins Potentiate Caspase-3 Activity in Immortalized Murine Neurons"; Neuroscience Letters; vol. 355; pp. 41-44, 2003.171M. Y. Morgan, "Branched Chain Amino Acids in the Management of Chronic Liver Disease Facts and Fantasies", J. of Hepatology, (1990) vol. 11 pp. 133-141.172M.A. Vandelli et al.; "2-Hydroxypropy1-beta-Cyclodextrin Complexation With Ursodeoxycholic Acid"; International Journal of Pharmaceutics, vol. 118; pp. 77-83, 1995.173M.A. Vandelli et al.; "2-Hydroxypropy1-β-Cyclodextrin Complexation With Ursodeoxycholic Acid"; International Journal of Pharmaceutics, vol. 118; pp. 77-83, 1995.174M.G. Allwood et al.; "Stability of Ampicillin Infusions in Unbuffered and Buffered Saline"; International Journal of Pharmaceutics, vol. 97; pp. 219-224, 1993.175M.L. Hanninen, "Sensitivity of Helicobacter pylori to Different Bile Salts", Eur. J. Clin. Microbiol. Infect., (1991) vol. 10, pp. 515-518.176Ma et al. "Ursodeoxycholic acid inhibits endothelin-1 production in human vascular endothelial cells" European Journal of Pharmacology, vol. 505 (pp. 67-74), 2004.177MacWalter et al.; "A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke"; Drug Safety; vol. 25, No. 13; pp. 943-963, 2002.178Mathai et al., "The effect of bile acids on the growth and adherence of Helicobacter pylori", Aliment Pharmacol Therap. (1991) 5, pp. 653-668.179McLeod et al., "Glucocorticoid-Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Hydrolysis in Rat Gastrointestinal Tract Contents", J. Pharm Sci., (1994) vol. 83, No. 9., pp. 1284-1288.180McLeod et al., "Glucocorticoid-Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Steady-State Pharamacokinetics in the Rat", Biopharmaceutics & Drug Disposition, (1994) vol. 15, pp. 151-161.181McLeod et al., "Synthesis and Chemical Stability of Glucocoritcoid-Dextran Esters: Potential Prodrugs for Colon-Specific Delivery", International J. of Pharmaceutics, (1993) vol. 92 pp. 105-114.182Michael B. Jacobs; "HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy"; www.PubMed.com ; pp. 3, Jun. 1, 1994.183 *Mishra et al., "Bleomycin-Mediated Pulmonary Toxicity: Evidence for a p53-Mediated Response" Am. J. Respir. Cell. Mol. Biol. (2000) vol. 22 pp. 543-549.184Mitsuyoshi H et al.; "Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants"; Biochemical and Biophysical Research Communications, vol. 263, No. 2; pp. 537-542, ISSN: 0006-291X, Sep. 24, 1999.185Miyajima et al., "Interaction of β-Cyclodextrin with Bile Salts in Aqueos Solutions", Chem. Pharm. Bull., (1986) vol. 34, No. 3 pp. 1395-1398.186Mohler et al., "Effect of Ursodeoxycholic Acid on HCV Replication in Subtyped Chronic Hepatitis C", Digestive Diseases and Sciences, (1996) vol. 41, No. 6 p. 1276.187Mollan, Jr. et al. "On of Aqueous Soluble Starch Conversion Products" Maltodextrin (pp. 308-349), 1995.188Montanari et al., "Oral administration of branched-chain amino acids (BCAAs) in liver cirrhosis (LC): effect on their intra- and extracellular pools", Chapter 67, in Advances in Ammonia Metabolism and Hepatic Encephalopathy, Soeters et al., eds., (1988) Elsevier Science Publishers B.V., pp. 519-526.189Moses et al., "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol Effectiveness and Reproducibility in Normal and Diabetic Subjects", Diabetes, (1983) vol. 32 pp. 1040-1047.190Murakami et al., "Effect of Bile Salts on the Rectal Absorption of Sodium Ampicillin in Rats", Chem. Pharm. Bull., (1984) vol. 32, No. 5 pp. 1948-1955.191N. F.H. Ho, "Utilizing Bile Acid Carrier Mechanisms to Enhance Liver an Small Intestine Absorption", Annals New York Academy of Sciences, (1987) 507:315-29.192N. Shibata et al.; "Molecular Biological Approaches to Neurological Disorders Including Knockout and Transgenic Mouse Models"; Neuropathology, vol. 22; pp. 337-349, 2002.193Na et al., "Cloud Point of Nonionic Surfactants: Modulation with Pharmaceutical Excipients", Pharmaceutical Research, (1999) vol. 16, No. 4 pp. 562-568.194Nagamatsu "Phase I Clinical Study of Ursodesoxycholic Acid" Jpn. Pharmacol. Ther. vol. 22, No. 6 (pp. 145-159) 1997.195Newman et al., "Starch", Analytical Profiles of Drug Substances, (1996) Bristol-Myer Squibb Pharmaceutical Research Institute, New Brunswick, NJ, pp. 523-577.196Nishigaki, et al., "Ursodeoxycholic Acid Corrects Defective Natural Killer Activity by Inhibiting Prostaglandin E2 Production in Primary Biliary Cirrhosis", Digestive Diseases and Sciences, (1996) vol. 41, No. 7, pp. 1487-1493.197Notification Concerning Transmittal of International Preliminary Report on Patentability; PCT/US2006/008925; pp. 6, Apr. 16, 2008.198Oliva et al., "Ursodeoxycholate Alleviates Alcoholic Fatty Liver Damage in Rats", Alcohol Clin Exp Res., (1998), vol. 22, No. 7,pp. 1538-1543.199Osato et al., "Osmotic Effect of Honey on Growth and Viability of Helicobacter pylori", Digestive Diseases and Sciences, (1999) vol. 44, No. 3 pp. 462-464.200Ota et al.; "Metabolism of Bile Acids IV*. Absorption, Distribution, Excretion, and Metabolism of Orally Administered Ursodeoxycholic Acid in Rats"; Hiroshima Journal of Medical Sciences, vol. 26, No. 4; pp. 233-251, Dec. 1977.201P.J. Neveu, "The Effects of Thiol Moiety of Levamisole on Both Cellular and Humoral Immunity During the Early Response to a Hapten-Carrier Complex" Clin. Exp. Immunol. vol. 32, pp. 419-422, 1978.202P.J. Sinko, "Utility of Pharmacodynamic Measures for Assessing the Oral Bioavailability of Peptides. 1. Administration of Recombinant Salmon Calcitonin in Rats", Journal of Pharmaceutical Sciences, (1995) vol. 84, No. 11, pp. 1374-1378.203P.M. Preshaw et al., "Self-medication for the control of dental pain: what are our patients taking?", Dent Update vol. 21, pp. 299-301, 304, Sep. 1994.204P.P. But et al., "Ethnopharmacology of bear gall bladder: I" Journal of Ethnopharmacology vol. 47, pp. 27-31, 1995.205Panini et al., "The Influence of 2-Hydroxypropy1-β-Cyclodextrin on the Haemolysis Induced by Bile Acids", J. Pharm. Pharmacol., (1996) vol. 48 pp. 641-644.206Park et al.; "Cisplatin-Induced Apoptotic Cell Death in Mouse Hybrid Neurons Is Blocked by Antioxidants Through Suppression of Cisplatin-Mediated Accumulation of p53 but Not of Fas/Fas Ligand"; Journal of Neurochemistry, vol. 75, No. 3; pp. 946-953, 2000.207Parquet et al., "Bioavailability, Gastrointestinal Transit, Solubilization and Faecal Excretion of Ursodeoxycholic Acid in Man", European J. of Clinical Investigation, (1985) vol. 15 pp. 171-178. 1985.208Paumgartner et al., "Ursodeoxycholic Acid Treatment of Cholesterol Gallstone Disease", Scand J. Gastroenterol (1994) 29 Suppl 204: 28-31.209PCT International Search Report and Written Opinion, PCT/US2004/039507, 29 pages, Mailing Date Oct. 25, 2005.210PCT International Search Report PCT/US2004/039507 (12 pages), Mailing Date May 8, 2005.211PCT Notification of Transmittal of the International Search Report and Written Opinion PCT/US2006/008925, 10 pages, Mailing Date Jul. 21, 2006.212Podda et al., "Effect of Different Doses of Ursofeoxycholic Acid in Chronic Liver Disease", Digestive Diseases and Sciences, (1989) vol. 34, No. 12, Suppl. pp. 59S-65S.213Podda et al., "Gallstone Dissolution After 6 Months of Ursodeoxycholic Acid (UDCA): Effectiveness of Different Doses", J. Int. Med. Res., (1982) vol. 10 pp. 59-63.214Poupon, et al., "Ursodiol for the Long-Term Treatment of Primary Billary Cirrhosis", The New England Journal of Medicine, (1994) vol. 330, No. 19, pp. 1342-1347.215R. Panini et al.; "Improvement of Ursodeoxycholic Acid Bioavailability by 2-Hydroxypropyl-beta-Cyclodextrin Complexation in Healthy Volunteers"; Pharmacological Research; vol. 31, No. 314; pp. 205-209, 1995.216R. Panini et al.; "Improvement of Ursodeoxycholic Acid Bioavailability by 2-Hydroxypropyl-β-Cyclodextrin Complexation in Healthy Volunteers"; Pharmacological Research; vol. 31, No. 314; pp. 205-209, 1995.217R.E. Castro et al.; "The Bile Acid Tauroursodeoxycholic Acid Modulates Phosphorylation and Translocation of Bad via Phosphatidylinositol 3-Kinase in Glutamate-Induced Apoptosis of Rat Cortical Neurons"; American Society for Pharmacology and Experimental Therapeutics; pp. 34, Jun. 9, 2004.218R.L. Wynn, "New Reports on Dental Analgesics. NSAIDs and Cardiovascular Effects, Celecoxib for Dental Pain, and a New Analgesic-Tramadol With Acetaminophen" General Dentistry vol. 50, pp. 218-220, 222, May 2002.219R.L. Wynn, "Update on Nonprescription Pain Relievers for Dental Pain", General Dentistry vol. 52, pp. 94-98 ,Mar. 2004.220R.L. Wynn, "New Reports on Dental Analgesics. NSAIDs and Cardiovascular Effects, Celecoxib for Dental Pain, and a New Analgesic�Tramadol With Acetaminophen" General Dentistry vol. 50, pp. 218-220, 222, May 2002.221Remington: The Science and Practice of Pharmacy, Lippincott Williams and Wilkins, pp. 218, 2000.222Reynier et al. "Comparative Effects of Cholic, Chenodeoxycholic, and Ursodeoxycholic Acids on Micellar Solubilization and Intestinal Absorption of Cholesterol" J. of Lipid Research, vol. 22 (pp. 467-473), 1981.223Reynier et al., "Comparative Effects of Cholic, Chenodeoxycholic, and Ursodeoxycholic Acids on Micellar Solubilization and Intestinal Absorption of Cholesterol", J. Lipid Research, (1981) vol. 22 pp. 467-473. 1981.224Ribatti et al.; "Development of the Blood-Brain Barrier: A Historical Point of View"; The Anotomical Record (Part B: New Anat.); pp. 6, 2006.225Roda et al., "Improved Intestinal Absorption of an Enteric-Coated Sodium Ursodeoxycholate Formulation", Pharmaceutical Research, (1994) vol. 11, No. 5 pp. 642-647.226Roda et al., "Influence of Ursodeoxycholic Acid on Biliary Lipids", Scand J Gastroenterol (1994) 29 Suppl. 204:16-8.227Rodrigues et al. "Neuroprotection by a Bile Acid in an Acute Stroke Model in the Rat" Journal of Cerebral Blood Flow & Metabolism, vol. 22 (pp. 463-471), 2002.228Rodrigues et al., "The Site-Specific Delivery of Ursodeoxycholic Acid to the Rat Colon by Sulfate Conjugation", Gastroenterology (1995) vol. 109 pp. 1835-1844.229Rolandi et al., "Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis", Eur J. Clin Pharmacol (1991) 40:473-476.230S. Friman and J Svarik, "A Possible Role of Ursodeoxycholic Acid in Liver Transplantation", Scand J. Gastroenteral (1994) 29 Suppl. 204:62-4.231 *Sauna et al., "Disulfram, an old drug with new potential therapeutic uses for human cancers and fungal infections" Mol. Biosyst. (2005) vol. 1, pp. 127-134.232 *Scheithauer et al., "Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay" Cancer Drug Delivery (1986) vol. 3 No. 1, abstract.233 *Schuldes et al., "Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts" European Journal of Cancer (2001) vol. 37 pp. 660-667.234Scott L. Myers et al., "Solid-State Emulsions: The Effects of Maltodextrin on Microcrystalline Aging", Pharmaceutical Research, (1993) vol. 10, No. 9 pp. 1389-1391.235Simoni et al., "Bioavailability Study of a New, Sinking, Enteric-Coated Ursodeoxycholic Acid Formulation", Pharmacological Research (1995) vol. 31, No. 2 pp. 115-119.236 *Singhal et al., "Thalidomide in Cancer: Potential Uses and Limitations" BioDrugs (2001) vol. 15 No. 3, pp. 163-172.237Sinisalo et al., "Ursodeoxycholic Acid and Endothelial-Dependent, Nitric Oxide-Independent Vasodilatation of Forearm Resistance Arteries in Patients with Coronary Heart Disease", Br. J. Clin. Pharamcol., (1999) vol. 47 pp. 661-665.238Stefaniwsky et al., "Ursodeoxycholic Acid Treatment of Bile Reflux Gastritis", Gastroenterology (1985) vol. 89, pp. 1000-1004.239Strandvik et al., "Cystic Fibrosis: Is Treatment with Ursodeoxycholic Acid of Value?", Scand J Gastroenterol (1994) 29 Suppl. 204:65-7.240Sun Ah Park et al.; "Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand"; Journal of Neurochemistry, vol. 75, No. 3; pp. 946-953; ISSN: 0022-3042, 2000.241 *Takeda et al., "Prevention of Irinotecan (CPT-11)-Induced Diarrhea by Oral Alkalization Combined With Control of Defecation in Cancer Patients" International Journal of Cancer (2001) vol. 92 pp. 269-275.242Tan et al., "Studies on Complexation between β-Cyclodextrin and Bile Salts", International J. Pharmaceutics, (1991) vol. 74 pp. 127-135.243Tanahashi et al., "Treatment of Acute Ischemic Stroke: Recent Progress" Internal Medicine vol. 41, pp. 337-344, 2002.244Tanaka et al., "Ligand-Independent Activiation of the Glucocorticord Receptor by Ursodeoxycholic Acid", The Journal of Immunology (1996) 156:1601-1608, 1996.245 *The American Heritage Dictionary, Second College Edition, published 1982 by Houghton Mifflin Company, p. 1213.246Thorsteinn Loftsson et al., "The Effect of Cyclodextrins on the Solubility and Stability of Medroxyprogesterone Acetate and Megestrol Acetate in Aqueous Solution", International J. of Pharmaceutics, (1993) vol. 98 pp. 225-230.247U. Leuschner et al., "Ursodeoxycholic Acid Therapy in Primary Biliary Cirrhosis", Scand J. Gastroenteral (1994) 29 Suppl. 204:40-6.248V. Fontes et al., "Recurrent Aphthous Stomatitis: Treatment With Colchicine. An Open Trial of 54 Cases", Ann. Dermatol. Venereol. vol. 129, pp. 1365-1369 , (with abstract) 2002.249V.S. Kasture et al.,"Anticonvulsant activity of Albizzia lebbeck leaves" Indian Journal of Experimental Biology vol. 34, pp. 78-80, Jan. 1996.250V.S. Kasture et al.,"Anticonvulsive activity of Albizzia lebbeck, Hibiscus rosa sinesis and Butea monosperma in experimental animals" Journal of Ethnopharmacology vol. 71, pp. 65-75, 2000.251Van Caekenberghe et al., "In Vitro Synergistic Activity between Bismuth Subcitrate and Various Antimicrobial Agents against Campylobacter pylorids", Antimicrobial Agent and Chemotherapy, (1987) vol. 31, No. 9, pp. 1429-1430.252Verrips et al. "Effect of Simvastatin in Addition to Chenodeoxycholic Acid in Patients with Cerebrotendinous Xanthomatosis" Metabolism, vol. 48, No. 2 (pp. 233-238), Feb. 1999.253Villaneuva et al. "Effect of Bile Acids of Hepatobiliary Transport of Cisplatin by Perfused Rat Liver" Pharmacology and Toxicology, vol. 80, No. 3 (pp. 111-117), Sep. 29, 1996.254Wacker Biochem. Corp., advertisement, C&EN, 31 (Apr. 12, 1999).255Walker et al., "Intestinal Absorpotion of Ursodeoxycholic Acid in Patients With Extrahepatic Biliary Obstruction and Bile Drainage", Gastroenterology (1992) 102:810-815.256Wardlaw et al.; "Thrombolysis for Acute Ischaemic Stroke"; Cochrane Database of Systematic Views; Issue 3; pp. 98, 2003.257 *Williams et al., "The Proteasome Inhibitor Bortezomib Stabilizes a Novel Active Form of p53 in Human LNCaP-Pro5 Prostate Cancer Cells" Cancer Research (2003) vol. 63 pp. 7338-7344.258XP 002337363, May 10, 1998, XP (abstract).259XP 002337364, Oct. 7, 1988, XP (abstract).260XP 002337365, Jul. 8, 1987, XP (abstract).261XP 002337367, Feb. 1, 1994, XP (abstract).262Y. Hattori, et al.; "Ursodeoxycholic Acid Inhibits the Induction of Nitric Oxide Synthase"; European Journal of Pharmacology; pp. 147-150, 1996.263 *Yamaguchi et al., "Regulation of Bax Activation and Apoptotic Response to Microtubule-damaging Agents by p53 Transcription-dependent and -independent Pathways" Journal of Biological Chemistry (2004) vol. 279 No. 38, pp. 39431-39437.264 *Youlyouz et al., "Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents" Cell Death and Differentiation (2008) vol. 15 pp. 376-385.265Zentler-Munro et al., "Effect of Intrajejunal Acidity on Aqueous Phase Bile Acid and Lipid Concentrations in Pancreatic Steatorrhoea Due to Cystic Fibrosis", Gut (1984) vol. 25 pp. 500-507.266Ziv et al., "Bile Salts Facilitate the Absorption of Heparin from the Intestine", Biochemical Pharmacology, (1983) vol. 32, No. 5 pp. 773-776.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS20130064775 *Mar 2, 2011Mar 14, 2013Universite D'auvergne Clermont IUse of riluzole for treating or preventing the adverse effects of antineoplastic agentsCN102178685A *Mar 3, 2011Sep 14, 2011山东农业大学Application of taurochenodeoxycholic acid in protection of adrenal gland functionCN102178685BMar 3, 2011Dec 5, 2012山东农业大学Application of taurochenodeoxycholic acid in protection of adrenal gland function* Cited by examinerClassifications U.S. Classification514/171, 514/182, 552/550, 552/549International ClassificationC07J9/00, A61K31/575, C07J41/00Cooperative ClassificationA61K35/413, A61K45/06, A61K47/48123, A61K9/0095, A61K31/575, A61K31/718, A61K31/715European ClassificationA61K31/575, A61K31/715, A61K31/718, A61K35/413, A61K47/48H4R, A61K9/00Z6, A61K45/06Legal EventsDateCodeEventDescriptionSep 30, 2014FPExpired due to failure to pay maintenance feeEffective date: 20140810Aug 10, 2014LAPSLapse for failure to pay maintenance feesMar 21, 2014REMIMaintenance fee reminder mailedRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services